Tdi-11861 (a fast-acting male contraceptive) approved for human clinical trials by the end of 2026?
Saúde e medicinaOne-Off2m
FutuurVerificar disponibilidadeDados de resolução verificadosProbabilidade implícita atual
Não 93%
Não 93%Qualidade do mercado
31 / 100
Baixa qualidadeVolume 24h
—
Liquidez
248,5 €
Baixa liquidezTraders
10
Comentários
0
Dados do mercado
Atualizado há 2 minutos
Tendências
Mercados Relacionados
Perguntas relacionadas para dar contexto, não uma comparação de contratos equivalentes.
How many clinical trials will have started in Prospera by Dec 31, 2026?
FutuurWill tabernanthalog (TBG) undergo Stage II clinical trials by EOY 2026?
Manifold MarketsWill a drug that didn't go through human clinical trials be approved by 2034?
Manifold MarketsWill it be possible to obtain FDA approval for a drug based on protein folding stimulations without human clinical trials by 2035?
Manifold MarketsWill human tooth regrowth clinical trials succeed?
Manifold MarketsHow many West Nile neuroinvasive disease cases will be reported among New York City residents in 2026?
PolymarketRegras
Researchers Jochen Buck and Lonny Levin of Weill Cornell Medicine have discovered a fast-acting and temporary male contraceptive called tdi-11861.
- This substance, a soluble adenylyl cyclase (sac) inhibitor, works by stopping sperm from swimming, rendering the subject temporarily infertile.
- According to initial studies in mice, it takes effect within half an hour, and fertility returns within a day.
- However, despite the encouraging results in mice, more animal tests and human trials are required before it can be confirmed as a breakthrough in male contraception.
- This prediction market aims to determine whether tdi-11861 will be approved for human clinical trials before or on December 31, 2026.
- The outcome will be determined based on an official announcement from the relevant regulatory bodies or agencies, such as the FDA, or news reports from major news outlets that Futuur deems credible.
